Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)

Alnylam Pharma Stock Outlook: For new entrants, chasing the momentum at this point would offer poor risk-reward dynamics.

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.

The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year.

Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the ATTR-CM market in the next 3 years.

Alnylam's Amvuttra wins FDA approval for ATTR-CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.